Vaccines and Biodefense

Learn about the role biotechnology plays in the on-going fight against HIV/AIDS.

Since the development of the first vaccine by Edward Jenner in 1796, we have seen tremendous progress in our ability to prevent deadly childhood infections.

Paul A. Offit, M.D. is Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia. Dr. Offit received this year's BIO Humanitarian Award at the 2011 BIO International Convention in Washington, DC.  Dr. Dr. Dr.

Phyllis Arthur interviews Colonel Randall Larsen, CEO of the WMD Center, on the threat of a pandemic as portrayed in the movie Contagion which opens in theatres nationwide today.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Paul A. Offit, MD was named the 2011 Biotech Humanitarian Award winner.

Dr. Tettelin discusses his research in reverse vaccinology and as a pioneer of the pan-genome concept.

A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant.

As we celebrate World Health Day today, it is an opportunity to remember that vaccines represent one of the most important global health investments.

As Japan works to stabilize the crippled nuclear power plant in Fukushima, people are stocking up on potassium iodide tablets – one of the only drugs available to block the body's absorption of some radioactive materials.

Bringing biotechs into global health R&D.

The Biotechnology Industry Organization (BIO) will hold its Intellectual Property Counsels Committee Spring Conference and Meeting in Seattle, Washington from April 13-15.

When you see “Get Your Flu Vaccine Here” signs and banners outside pharmacies and in doctor’s offices, you might think, “isn’t it too late for that?” The answer is no.

Letters, Testimony & Comments

May 17 2012
  The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid...
March 2 2012
Re: Draft 2013 Call Letter Dear Mr. Blum and Mr. Spitalnic: The Biotechnology Industry Organization (BIO) appreciates this...
January 20 2012
Re: Request for Comments Regarding Enhancements to the Part C and Part D Plan Ratings The Biotechnology Industry Organization (BIO)...
September 30 2011
  Re:  Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
August 9 2011
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the core set of health quality measures for the...

Press Releases

March 8 2012
Washington, DC (March 8, 2012) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood...
November 15 2011
Reauthorization demonstrates government commitment to national security priority Washington, D.C. (November 15,...
June 15 2011
WASHINGTON, D.C. (Wednesday, June 15, 2011) - High-level members of the Obama Administration will gather with leaders...
May 4 2011
WASHINGTON, D.C. (Tuesday, May 04, 2011) - The Biotechnology Industry Organization (BIO) announced today its...
April 19 2011
WASHINGTON, D.C. (Tuesday, April 19, 2011) - The Biotechnology Industry Organization (BIO) announced today that Dr. J...